Evidence map›Paper›PMID 34794689›Full record

Observational studyJournal of the American College of Cardiology2021

Effectiveness of Implantable Cardioverter-Defibrillators to Reduce Mortality in Patients With Long QT Syndrome.

Meng Wang, Derick R Peterson, Spencer Rosero, Scott McNitt, David Q Rich, Christopher L Seplaki, Bronislava Polonsky, Ilan Goldenberg, Wojciech Zareba

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of the American College of Cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Implantable cardioverter defibrillators for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia? (Not so fast, Louis).Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Meng WangClinical Cardiovascular Research Center, Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA; Division of Epidemiology, Department of Public Health Sciences, University of Rochester Medical Center, Rochester, New York, USA.
Derick R PetersonDepartment of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, USA.
Spencer RoseroDivision of Cardiology, University of Rochester Medical Center, Rochester, New York, USA.
Scott McNittClinical Cardiovascular Research Center, Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA.
David Q RichDivision of Epidemiology, Department of Public Health Sciences, University of Rochester Medical Center, Rochester, New York, USA; Division of Pulmonary and Critical Care, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA; Department of Environmental Medicine, University of Rochester Medical Center, Rochester, New York, USA.
Christopher L SeplakiDivision of Epidemiology, Department of Public Health Sciences, University of Rochester Medical Center, Rochester, New York, USA; Department of Psychiatry, University of Rochester Medical Center, Rochester, New York, USA.
Bronislava PolonskyClinical Cardiovascular Research Center, Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA.
Ilan GoldenbergClinical Cardiovascular Research Center, Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA.
Wojciech ZarebaClinical Cardiovascular Research Center, Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA. Electronic address: wojciech_zareba@urmc.rochester.edu.
University of Rochester Medical Center · US

Funding

LONG QT SYNDROME--POPULATION, GENETIC, &CARDIAC STUDIESR01HL033843 · NHLBI · UNIVERSITY OF ROCHESTER · PI MOSS, ARTHUR J. · 1985 to 2011
$5.9M
Clinical and Basic Science Studies in Long QT Syndrome Type 3R01HL123483 · NHLBI · UNIVERSITY OF ROCHESTER · PI KASS, ROBERT S, ZAREBA, WOJCIECH · 2014 to 2018
$3.7M
LONG QT SYNDROME--GENETIC STUDIESR01HL051618 · NHLBI · UNIVERSITY OF ROCHESTER · PI MOSS, ARTHUR J. · 1993 to 2002
$1.2M
NHLBI NIH HHS R01 HL033843NHLBI NIH HHS R01 HL051618NHLBI NIH HHS R01 HL123483
6 · The paper itself

Abstract

backgroundThe effectiveness of implantable cardioverter-defibrillators (ICDs) on reducing mortality has not been well studied in patients with long QT syndrome (LQTS).

objectivesThis study aimed to assess the survival benefits of ICDs in the overall LQTS population and in subgroups defined by ICD indications.

methodsThis study included 3,035 patients (597 with ICD) from the Rochester LQTS Registry with a QTc ≥470 milliseconds or confirmed LQTS mutation. Using multivariable Cox proportional hazards models, the risk of all-cause mortality, all-cause mortality before age 50 years, and sudden cardiac death (SCD) were estimated as functions of time-dependent ICD therapy. Indication subgroups examined included patients with: 1) nonfatal cardiac arrest; 2) syncope while on beta-blockers; and 3) a QTc ≥500 milliseconds and syncope while off beta-blockers.

resultsDuring the 118,837 person-years of follow-up, 389 patients died (137 before age 50 years, and 116 experienced SCD). In the entire population, patients with ICDs had a lower risk of death (HR: 0.54; 95% CI: 0.34-0.86), death before age 50 years (HR: 0.29; 95% CI: 0.14-0.61), and SCD (HR: 0.22; 95% CI: 0.09-0.55) than patients without ICDs did. Patients with ICDs also had a lower risk of mortality among the 3 indication subgroups (HR: 0.14; 95% CI: 0.06-0.34; HR: 0.27; 95% CI: 0.10-0.72; and HR: 0.42; 95% CI: 0.19-0.96, respectively).

conclusionsICD therapy was associated with a lower risk of all-cause mortality, all-cause mortality before age 50 years, and SCD in the LQTS population, as wells as with a lower risk of all-cause mortality in indication subgroups. This study provides evidence supporting ICD implantation in patients with high-risk LQTS.

Indexed as

AdolescentAdrenergic beta-AntagonistsAdultAgedAged, 80 and overChildChild, PreschoolDeath, Sudden, CardiacDefibrillators, ImplantableFemaleFollow-Up StudiesHumansInfantLong QT SyndromeMaleMiddle AgedAdrenergic beta-Antagonistsgenotypeimplantable cardioverter-defibrillatorlong QT syndromemortalitymutationsudden cardiac death

Identifiers

PMID34794689
PMCPMC8608269
OpenAlexW3214228823

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.